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ABSTRACT 
A plasmid DNA vaccine is able to induce both humoral and cellular immune responses; however, the kinetic change of 
the Th1/Th2 response, antibody avidity, cytokine secretion, and neutralization activity after different priming and 
boosting strategies have not been evaluated. A plasmid DNA, designated pCBD2 and previously shown to efficiently 
induce an immune response very similar to that by a wild type virus, was evaluated kinetically in this study. Our results 
suggest that a DNA vaccine delivered by the gene gun (gg) route produced higher and longer DENV-2-specific anti-
body titers than those induced through the intramuscular (im) route. Although the gg group induced a Th2 response and 
im delivery induced a Th1 response, priming by gg delivery, followed by a boosting by im delivery, did not shift the 
immune response from a Th2 to Th1 response. Furthermore, the antibody avidity (AI) measured by ELISA demon-
strated a gradual increase of AI from low (AI range from 6.8% - 9.6%) on day 42 to high (AI value > 30) on day 119 in 
all but the gene-gun immunization group, in which an AI value of 23 was observed. Although there was lower avidity in 
the gg group, the mice sera from all three groups of mice demonstrated significant neutralization activity. This is the 
first report about the kinetics of immunogenicity of a DNA vaccine through different administration strategies, which 
suggests that gene gun delivery of a DNA vaccine can induce an immune response containing both neutralizing and 
nonneutralizing antibodies at high titers important for neutralization. 
 
Keywords: Dengue; DNA Vaccine; Immunological Response; Gene Gun Delivery 
1. Introduction 
Dengue is a mosquito-borne viral disease in humans and 
is a significant public health threat in the tropics and sub- 
tropics, where billions of people are at risk and an esti-
mated 100 million new infections occur each year [1]. 
There are four dengue virus serotypes, named dengue 
virus serotype 1 (DENV-1) through dengue virus sero-
type 4 (DENV-4). These viruses form an antigenically 
distinct subgroup within the flavivirus family [2]. One 
infected by any of these viruses may be either asympto- 
matic or inflicted with a self-limited febrile illness known 
as dengue fever (DF). In a small percentage of cases, 
however, infection results in a life-threatening dengue 
hemorrhagic fever or dengue shock syndrome (DHF/DSS) 
[3]. Despite the magnitude of public health implications 
DF and DHF have, vector control, which has proven dif- 
ficult and costly to sustain over time, is currently the only 
available control measure [4]. Vaccines are one of the 
most promising strategies for preventing DF and DHF, 
although they are currently unavailable for dengue vi- 
ruses [5].  
DENV are enveloped, RNA viruses that encode 10 
proteins; three are structural proteins: capsid (C), mem-
brane (M) with its precursor (pr), and envelope (E), and 
seven are nonstructural (NS) proteins: NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5 [6]. In flaviviruses, the E 
protein is involved in a number of important functions 
related to viral infection, such as receptor binding and 
membrane fusion [7]. E protein antibodies neutralize vi- 
rus activity in vitro and in vivo [8,9]. Furthermore, sub- 
viral particles consisting only of prM and E proteins are 
highly effective in generating a protective immune re- *Corresponding author. 
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sponse against DENV in mice [10]. Recent studies sug-
gested that most of the virus-neutralizing epitopes, im-
portant in immunity, are located on the virion surface of 
the structural E glycoprotein and are the target for which 
the vaccine is designed [11].  
There are currently no licensed vaccines available for 
dengue infection, although several vaccine candidates are 
in pre-clinical and clinical trials [5,12,13]. The leading 
candidates are live-attenuated dengue virus vaccines (LAV) 
in Phase 2 clinical trials in the United States and Thai-
land [5,14]. Attenuated vaccines are inexpensive and pro- 
duce long-term durations in immune responses; however, 
interference among the four dengue viruses during pro- 
pagation in vaccinated hosts may cause an imbalanced 
immune response to four serotypes, which may cause an 
elevated disease severity following subsequent dengue 
virus infections. There are continued efforts for develop-
ing alternative vaccine candidates [15]. DNA vaccine 
technology is a novel approach for preventing infectious 
diseases [16]. Inoculating animals with purified plasmid 
vectors (DNA) via the intramuscular (im) or intradermal 
(i.d.) route leads to the expression of the recombinant 
vector-encoded protein in transfected cells, resulting in 
the stimulation of a protein-specific immune response. 
Such responses include induction of antibodies, genera-
tion of CD4 Thelper lymphocytes and CD8 cytotoxic lym-
phocytes (CTL), and protection against a range of viral 
infections [17]. Recent studies demonstrate that DNA 
vaccines containing full-length prM and E (prM-E) genes 
of dengue-1 and dengue-2 viruses are immunogenic in 
mice [18-21], and that a dengue-1 prM-E DNA vaccine 
is also immunogenic and partially protective in rhesus 
and Aotus monkeys [22]. DNA vaccines that encode an-
tigenic proteins have immunized against dengue viruses, 
flaviviruses such as Murray Valley, encephalitis (MVE), 
the encephalitis virus (JEV), and tick-born encephalitis 
viruses (TBEV) successfully in experiments [23-27]. 
These vaccines are likely to be inexpensive, safe, and 
easy to produce. 
Since DNA vaccines are able to induce both humoral 
and cellular immune responses, an important considera-
tion in the application of DNA vaccines is the immuniza-
tion routes employed. DNA vaccinations were performed 
predominantly using two different methods: i.d./im injec-
tion and gene gun delivery. Injection delivers purified 
DNA into the extracellular space for uptake by a limited 
numbers of muscle fibers, while particle bombardment 
using gene gun delivers DNA directly into the intraepi-
dermal cells where the professional antigen presenting 
Langerhans cells (LCs) are situated [28]. Gene gun de-
livery requires a smaller amount of DNA compared to 
the injection method. Furthermore, a few studies have 
suggested that the two vaccination techniques differ in 
the immune response induced [29]. While injections tend 
to induce a Th1 response, the gene gun response is more 
of a Th2 response. A lot of efforts has been trying to re-
verse the predominantly Th2 immune response after gene 
gun delivery by co-delivery of the IL-2, IL-7 or IFN-γ 
genes [30-32]. It is unknown whether the Th1-type re-
sponse can be enhanced through DNA vaccination prim-
ing by gene gun delivery and boosted by im injection.  
In formal studies, we have identified a potential mem-
brane retention region between E-397 and E-436 of the 
DENV-2 virus E protein [10]. A chimeric plasmid was 
formed by replacing the membrane-anchoring region of 
the E protein, E-397 to E450, with the corresponding 
region in the Japanese encephalitis virus (JEV). This 
DEN-2-JE virus chimeric plasmid, consisting of prM and 
80% E (E-1 to E-397) of DENV-2, followed by 20% E 
from JEV (corresponding to DENV-2 E-397 to E450), 
secreted prM/M and E proteins efficiently in plasmid 
transformed COS-1 cells. The chimeric DENV-2 plasmid 
can form subviral particles (SVP), whose immunogenic-
ity is very similar to that of a wild type virus. Also, the 
immune response after im immunization of DENV-2 
chimeric plasmids correlated with the efficiency of prM/ 
M and E secretion. A similar chimeric DNA plasmid has 
also been constructed to produce SVP in the St. Louis 
encephalitis virus (SLEV) and the West Nile virus (WNV), 
which protects from wild type virus challenges in mice 
and horses after DNA immunization [33]. 
Our present work deals with the characterization of the 
antibody responses induced in mice immunized with a 
recombinant plasmid encoding the prM and E genes of 
dengue virus type 2, administered either i.m or i.d with 
different priming and boosting strategies. The effects of 
the immune response and antibody avidity elicited by 
different immunization regimens and/or inoculation routes 
were analyzed and compared. This is the first report con- 
cerning the simultaneous comparison of different ad- 
ministration routes for delivering a DNA vaccine, and 
adds further support for the utility of dengue DNA vac- 
cines. 
2. Materials and Methods 
2.1. Cells and Viruses 
The Hawaii strain of DENV-1, the 16681 strain of 
DENV-2, the H87 strain of DENV-3, and the H241 strain 
of DENV-4 were used. Baby hamster kidney (BHK)-21 
cells were grown at 37˚C in Dubelco’s medium (D-MEM) 
with 10% FBS, and were used to determine the wild-type 
viruses in tissue culture supernatants for the plaque assay 
and the 50% plaque reduction neutralization test (PRNT- 
50), as described previously [34]. C6/36 cells derived 
from mosquito cells were obtained from the American 
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Type Culture Collection (ATCC, Manassas, VA) and 
grown at 28˚C in MEM with 10% FBS and amino acids, 
to grow wild-type DEN viruses. Culture fluids harvested 
from C6/36 mosquito cells infected with each of these 
viruses were used for neutralization tests and ELISA 
experiments. For T-cell stimulation assays, the culture 
fluids were further purified by centrifugation at 20,000 
rpm for two hours at 4˚C, and the equivalent amount of 
purified viral antigens and VLPs determined at OD 1.2 
was used for stimulation.  
2.2. Construction of the Plasmid and Virus-Like  
Particle (VLP) Expression 
The pcDNA3-based vaccine plasmids encoding the prM 
and E genes of the DENV-2 16681 strain, afterwards 
named pCBD2, have been constructed as described be-
fore [10]. A mixture of 100 µg of DNA was used as the 
DNA vaccine. The DNA was purified using a plasmid 
DNA purification kit and was kept in sterile distilled wa-
ter at a concentration of 1 mg/mL for transfection. The 
VLPs of DENV-2 were expressed by electroporating 
pCBD2 into COS-1 cells and then partially purifying 
from clarified tissue culture medium by ultracentrifuga-
tion at 19,000 rpm for 8 to 16 hours, as previously de-
scribed [35]. The purified DENV-2 VLPs were used as 
antigens in ELISA and the T-cell stimulation assay.  
2.3. Preparation of Cartridges for Genetic  
Immunization 
For the pCBD2 plasmid DNA to be tested, 25 mg of 
1.6-micron gold powder was weighed into a microcen-
trifuge tube. One hundred microliters of 50 mM sper-
midine (Sigma-Aldrich, St. Louis, MO) was added to the 
tube, and the gold was resuspended by vortexing and 
brief centrifugation. Twenty-five micrograms of pCBD2 
plasmid DNA was added to the tube, followed by the 
addition of 100 µL of 10% CaCl2 (Sigma-Aldrich, St. 
Louis, MO) while gently vortexing to effective precipita-
tion of the DNA onto the gold beads. The precipitation 
reaction was allowed to proceed for 10 minutes on the 
bench top, after which the gold beads were collected by 
brief microcentrifugation and washed three times with 
absolute ethanol (J.T. Bakers Inc., Gardena, CA) to re-
move excess precipitation reagents. The washed gold- 
DNA complex was then resuspended in a solution of 
0.05 mg/mL of polyvinylpyrrolidone (PVP) (360 kD; 
Sigma Chemicals, Inc.) in absolute ethanol to a volume 
of 3.6 mL (for mice). This slurry was injected into a Te-
fzelR tube (McMaster-Carr, Chicago, IL) that was posi-
tioned in a tube turner to coat the inside of the TefzelR 
tube with the gold-DNA complex. After the tube turning 
procedure was completed and the ethanol dried, the tubes 
were cut into 0.5-inch shots of vaccine, which were 
stored at 4˚C in the presence of desiccators. Each shot 
contained 0.25 µg of DNA (a function of the amount of 
gold per shot and the DNA:gold ratio), a parameter that 
was previously established to be nearly optimal for ge-
netic immunizations [36]. At least one hour before use, 
the shots were moved to room temperature and loaded 
into the XR1 gene gun device (Bio-Rad, Hercules, CA.) 
for delivery. 
2.4. Animals and Immunization 
Twelve female BALB/c mice 4 - 6 weeks old, purchased 
from the Laboratory Animal Center of National Taiwan 
University, College of Medicine, will be accommodated 
to the environment seven days before study. The mice 
will be divided into three groups to evaluate the induc-
tion of antibody and protective immunity: group gg will 
be primed and boosted with DNA through gene gun de-
livery, group im will be primed and boosted with DNA 
through intramuscular delivery, and group gg + im will 
have gene gun delivery first followed by one shot of in-
tramuscular delivery 3 weeks later. The use of animals 
has been reviewed and fully complied with the Commit-
tee of Animal Review of the institute. For gene gun im-
munization with a pCBD2 DNA vaccine, a hand-held, 
helium-driven Helios gene delivery system (Bio-Rad, 
Hercules, CA) will be used. Gene gun injection into the 
abdominal epidermis will be performed using a helium 
pressure setting of 400 lb/inch2. All animals from each 
group were primary immunized by pCBD2 with the des-
ignated delivery routes. For higher immunization effi-
ciency, a booster immunization will be given three to 
four weeks after the primary immunization. The booster 
doses contain the same amount of DNA as the primary 
dose. For intramuscular immunization, 100 µg of plas-
mid at a concentration of 1 µg/µL in PBS will be admin-
istered, and another booster immunization with the same 
concentration as the primary will be given 3 weeks later. 
For gene gun delivery, each mouse will be given 4 shots 
for each immunization. Mice were bled from the retro- 
orbital sinus 2 and 4 weeks after primary and before 
booster immunization, and also at 2, 3, 2, 4 week inter-
vals after booster immunization. The serum samples were 
evaluated for DENV-2-specific antibodies by ELISA and 
PRNT as described below.  
2.5. Dengue Virus Plaque-Reduction  
Neutralizing Antibody Assay (PRNT) 
Various dilutions of serum samples from the immunized 
mice were prepared in EMEM not containing FCS and 
antibiotics. Diluted serum was incubated at 56˚C for 30 
min. to inactivate the complement. The serum sample 
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(100 mL) was then mixed with an equal volume of 
DENV-2 culture supernatant containing 30 pfu of the 
virus. The virus-antibody mixture was incubated at 4˚C 
for 1 h before it was added to a 24-well plate containing 
a 70% confluent monolayer of BHK-21 cells. The plates 
were incubated at 37˚ for 1 h with gentle rocking every 
15 min. The wells were then overlaid with 0.5 mL of 
0.6% methylcellulose prepared in E-MEM supplemented 
with 1% FCS and incubated at 37˚ in 5% CO2 for 5 days. 
Plaques were stained with 1% crystal violet and counted. 
The 50% PRNT titers (PRNT50) were calculated as the 
reciprocal of the highest dilution resulting in a 50% re-
duction in plaques compared to that of a control virus 
with no added antibodies as determined by probit analy-
sis. A pool of the sera of animals that were collected be-
fore they were primed was used as the negative control 
for PRNT.  
2.6. ELISA 
The ELISA used to study the antibody response was 
performed in a 96-well plate. DENV-2 infected C6/36 
cells, or purified DENV-2 E-containing virus-like parti-
cles (VLP), were used as the antigens. The DENV-2 VLP 
antigens were independently titrated against a positive 
control serum sample with a twofold dilution series and 
standardized by selecting a dilution that yielded an ab-
sorbance of 0.8 to 1.2 at 450 nm (A450). The C6/36 
cell-based antigen preparation was performed as follows. 
1 × 104 C6/36 cells were seeded into each well of a 
96-well plate. The next day, the 16681 strain of DENV-2 
with multiplicity of infection (m.o.i) 0.1 was used to in-
fect the cells at 37˚C for 1 h. The wells were then washed 
with PBS and cultured in MEM with 10% FBS at 28˚C 
for 7 days before being fixed with 10% acetone in PBS at 
4˚C for 10 minutes. The plates were then blocked by 1% 
bovine serum albumin (BSA) at room temperature for 1 
hour and stored at −20˚C until needed for use. Also, the 
DENV-2 rabbit antiserum (kindly provided by Dr. GJ 
Chang at US-CDC) with 1:3500 dilution in carbon-
ate-bicarbonate buffer (45.3 mM NaHCO3, 18.2 mM 
Na2CO3 [pH 9.6]) was added to each well. The coating 
was done overnight at 4˚C. The following day, the wells 
were blocked by 1% BSA in the wash buffer (PBS con-
taining 0.1% Tween 20) at room temperature for 1 hour, 
and then the VLPs or virus culture supernatants of 
DENV-2 were added to each well, which allowed for 
saturated binding of antigens to the wells of ELISA plate. 
The immunized mice serums (50 µL/well) were added to 
the plates and incubated for 2 hours at room temperature. 
The plates were later washed six times with washing 
buffer, and incubated with horseradish-peroxidase (HRP)- 
conjugated goat anti-mouse IgG (50 µL/well at 1:5000  
dilution) (Jackson ImmunoResearch, Pennsylvania, USA) 
in blocking buffer for 1 hour. Afterward, the plates were 
washed six times with washing buffer, and the colorimet-
ric reaction will be developed with the substrate or-
tho-phenylene-diamine (OPD), prepared according to 
manufacturer’s instructions (Sigma-Aldrich, St. Louis, 
MO) for 4 - 5 minutes and stopped by the addition of 50 
µL/well of 3N HCl. Absorbance at 490 nm was measured 
using a microplate reader. Each control and test group 
consisted of three replicate wells, and each experiment 
was repeated at least three times. Antibody isotyping 
ELISAs were done in a similar fashion, however, anti- 
mouse IgG-HRP, anti-mouse IgG1-HRP, or anti-mouse 
IgG2a-HRP conjugates (PharMingen, San Diego, Cali-
fornia), were added. 
2.7. Antibody Avidity Analyses 
Antibody avidity measurements were performed by com- 
paring antibody binding to antigens in the presence and 
absence of 6 M urea in a standard ELISA [37,38]. Briefly, 
sera were diluted so as to obtain a standard ELISA ab- 
sorbance of between 0.8 and 1.5. ELISA was performed 
in duplicate microtiter plates. After antibody binding, 
both plates were washed three times with wash buffer. 
200 µL of wash buffer was added per well to one plate, 
and 200 µL of wash buffer per well containing 6 M urea 
was added to the other plate. Both plates were incubated 
for 5 min at room temperature. The buffers were re- 
moved and the plates were washed three more times with 
wash buffer. Incubations with conjugate and substrate 
were carried out according to the standard ELISA proto- 
col. The avidity index (AI) was calculated as: 
100 × {(A450D2-VLP[+urea] − A450NC[+urea])/(A450D2-VLP[−urea] − 
A450NC[−urea])}.  
2.8. Spleen T-Cell Stimulation Cytokine ELISA 
Two weeks after the last immunization, spleen cells were 
isolated and stimulated in vitro by incubating with the 
dengue antigens in RPMI medium at a concentration of 2 
× 106 cells/mL. Two types of DENV-2 antigens were 
used here as the stimulant, including DENV-2 culture 
supernatants and VLPs. These two types of antigens were 
adjusted to the equivalent amount by using ELISA with 
serial dilution to 1:10 with OD > 2.0 (at 10 g/mL). 
Fixed amounts of DENV-2 E antigens were incubated 
with 107 splenocytes/well in a 24-well plate in 2 mL of 
RPMI 1640 medium supplemented with 10% FCS and 
antibiotics at 37˚C in 5% CO2. Negative controls in-
cluded untransfected COS-1 cell supernatants and vi-
rus-free C6/36 cell supernatants. As the positive control 
for viability, spleen cells were stimulated with ConA 
(purchased from Sigma-Aldrich and used as 1 µg/mL) or 
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anti-CD28 antibodies (purchased from Biolegend, San 
Diego, CA and used as final concentration of 1 µg/ml). 
Spleen cells were incubated with the stimulating antigens 
overnight in a cell culture incubator, and 200 µL of each 
of the reactions were transferred in triplicate to ELISA 
plates. Aliquots of the culture supernatant were collected 
24 and 48 hours later and assayed for interferon (IFN)-γ 
and interleukin (IL)-4 by the ELISA kit purchased from 
eBioscience (San Diego, California) by following the 
manufacturer’s protocol. In brief, 96-well plates were 
coated with 0.4 mg/well purified rat anti-mouse IL-4 or 
IFN-γ antibodies. Wells were blocked with 1% BSA in 
wash buffer. We added 100 µL of antigen-stimulated 
spleen-cell suspensions to the wells, and plates were in-
cubated at 4˚C overnight. The plates were washed before 
the addition of diluted biotinylated anti-mouse IL-4 or 
IFN-γ (100 µL/well) and incubated for 1 h at 37˚C. The 
plates were washed again before the addition of diluted 
anti-mouse streptavidin-HRP conjugate (100 μL/ well) 
and incubated for 1 h at 37˚C. Color was developed by 
adding 100 μL/well of TMB substrate solution. The reac-
tion was stopped by adding 50 μL of 5 N H2SO4. Ab-
sorbance was read at 450 nm in a microplate reader. As 
little as 15 pg/mL of both IFN-γ and IL-4 could be de-
tected with these ELISAs. 
tween two groups were analyzed for significance using 
ANOVA and t tests, respectively. Logarithmic transfor-
mations of the reciprocal PRNT50 titers of the mice in 
each immunization group were made to stabilize vari-
ance. 
3. Results 
3.1. Serum Antibody Response to Immunization  
in Mice 
Three groups of 4 BALB/c mice 4 weeks old were im-
munized with DENV-2 plasmid pCBD2 by direct im 
injection of DNA, gene gun delivery to the skin, or both 
as described in materials and methods section. The anti-
body responses of these mice were compared among 
these groups. Serum samples were obtained from mice at 
various times, and anti-DENV-2 specific antibody re-
sponses were determined by ELISA. Figure 1 shows that 
anti-DENV-2 IgG antibodies were detectable in all 
mouse groups 28 days after immunization. Levels of 
these antibodies increased five weeks after the second 
booster dose (on day 63) and were particularly enhanced 
when the immunization was primed and boosted by gene 
gun. At these points in time, the anti-E antibody response 
in mice immunized by im DNA inoculation was compa-
rable to that in mice injected by gene gun followed by im. 
However, there is a statistically significant higher anti-
body response both in the level and duration for the  
2.9. Statistical Analysis 
Differences in responses across multiple groups and be-  
 
 
Figure 1. Kinetics of antibody response of 4-week-old BALB/c mice immunized with pCBD2 plasmid DNA expressing the 
secretory forms of the E protein by different methods of immunization. Booster injections were given on postimmunization 
days 28. Serum samples were obtained from mice on the indicated days, before booster immunization and the samples were 
stored at −20˚C. Serum samples were diluted 1:2400 and assayed for anti-DENV-2 antibody response by ELISA. Each col-
umn shows the mean antibody response for a group as ELISA optical density (OD): left diagonal stripes, mice immunized by 
intramuscular (im) inoculation; horizontal stripes, mice immunized by gene gun (gg); blank, mice immunized by gene gun + 
im. The t-test was performed by comparing the averages of OD value between the gg and im groups and p-values were indi-
ated. c   
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gene-gun group compared to the gg + im and im group 
on day 84 and 119 post-immunization (p < 0.05). At no 
time were any statistically significant differences seen 
between groups in the antibody responses of mice when 
DENV-2 infected cells or when a VLP was used as the 
antigen for ELISA. The results suggested that gene-gun 
delivery of a DNA vaccine induced a higher and longer 
duration of DENV-2-specific antibody responses com-
pared to im delivery. 
3.2. Isotype Analysis of Anti-E Antibodies 
To further analyze the immune response to the E protein 
among three groups of mice, end-point titers of anti-E 
IgG1 and IgG2a antibodies were determined (Figure 2). 
Delivery of DNA to the skin by gene gun preferentially 
induced IgG1-type immunoglobulins with a mean IgG1/ 
IgG2a ratio of 1.32 ± 0.51. However, the im inoculation 
of plasmid DNA preferentially induced IgG2a antibodies 
with a mean IgG1/IgG2a ratio of 0.59 ± 0.17. The gg + 
im group induced a IgG1-type immunoglobulin similar to 
that by the gene gun group, with a mean IgG1/IgG2a 
ratio of 1.36 ± 0.36. The IgG antibody isotypes were fol-
lowed post-immunization for all three groups on days 63, 
84, and 119, and the results were similar to those seen on 
day 42. These data suggest that im inoculation of DNA 
produced a Th1 immune response and that gene gun- 
based delivery led to a Th2 immune response. Further-
more, the immunoglobulin isotypes were determined by 
a procedure during primary immunization, and the 
switched procedure during booster immunization did not 
shift the immunoglobulin isotype presentation.  
3.3. Cytokine Production by Spleen Cells from  
Immunized Mice 
Spleen cells from different groups of immunized mice 
were cultured in vitro in the presence or absence of viral 
antigens or VLP proteins of DENV-2. Levels of IFN-γ 
and IL-4 were measured in these cultures 48 h later. 
Figure 3 shows that spleen cells from mice immunized 
with the DNA vaccine produced moderately lower levels 
of IL-4 and IFN-γ in the presence of the DENV-2 VLP 
protein compared to those in the presence of DENV-2 
viral antigens. High levels of IL-4 and very low levels of 
IFN-γ were seen in mice immunized with pCBD2 by 
gene gun. Similarly, delivery of pCBD2 by gene gun 
followed by im induced high levels of IL-4 and low lev-
els of IFN-γ as seen in the gene gun group. Levels of 
IL-4 in spleens from gg + im immunized mice were lower 
than those in spleens from mice immunized by gene gun. 
In mice immunized im with pCBD2, IFN-γ levels were 
very high and IL-4 levels were very low. The presence or 
absence of CD28, the co-stimulatory molecules of the 
CD4 T cell, didn’t influence the cytokine expression dur- 
ing the co-culture process. These results suggest that 
gene gun-based delivery of plasmid DNA induced Th2 
immune responses. These responses were not considera-
bly affected by whether the pCBD2 DNA plasmid was 
delivered later on by im for boosting which indicated that 
the primary immunization determined the immune mem-
ory and the booster dose did not shift the memory from 
Th2 to Th1 response. On the contrary, im inoculation of 
pCBD2 gave a Th1-dominated immune response with 
high levels of IFN-γ and low levels of IL-4. 
 
 
Figure 2. IgG1 and IgG2a isotype analysis of anti-E antibodies of 4-week-old BALB/c mice immunized with pCBD2 plasmid 
DNA by different methods of immunization. Each column shows the mean IgG1/IgG2a ratios: left diagonal stripes, mice im-
munized by intramuscular (im) inoculation; horizontal stripes, mice immunized by gene gun (gg); blank, mice immunized by 
gene gun + im. 
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Figure 3. Cytokine response of 4-week-old BALB/c mice immunized with pCBD2 plasmid DNA generated by different meth-
ods of immunization. Different groups indicated different types of antigens were used for stimulation of splenocytes for cyto-
kine release. NC: no antigen, PC: ConA, VLP: DENV-2 VLP, D2: partially purified DENV-2 viruses from C6/36 culture su-
pernatant. Anti-CD28 antibody was also added in case CD28 was needed as a co-stimulatory molecule. 
 
3.4. Kinetics of Antibody Avidity 
Measurement of the kinetics of antibody avidity by 
ELISA demonstrated a low antibody avidity index (AI 
range from 6.8% - 9.6%) in mice of all three groups on 
day 42 (equivalent to 2 weeks after the last immunization) 
followed by gradual increase of antibody avidity (Figure 
4). By day 119 (equivalent to 3 months after the last im-
munization), all mice in different vaccination groups pre- 
sented high antibody avidity (AI value > 30) except the 
gene-gun immunization group, in which an AI value of 
only 23 was observed. Noticeably, the mice from im 
group showed a sharp increase in antibody avidity on day 
63 one month after booster immunization and remained 
stable afterwards. Significant differences in antibody 
avidity indices among different vaccine groups on day 63, 
84, or 119 were determined individually by ANOVA, 
which suggested a statistical significance (P < 0.001). 
The im group had the highest antibody avidity compared 
to the gg group on all days tested including day 63, 84 
and 119; however, the significant difference was only 
seen between the im and gg + im group on day 63 and 84. 
The AIs for groups that received vaccines through gene 
gun were not significantly different from the AI for the 
gene gun followed by im group except on day 63. These 
data suggested that DNA immunization through the im 
route gave rise to higher antibody avidity compared to 
the gene gun immunization route. The im route would 
increase the antibody avidity 9.6% on day 119, even 
though the initial immunization was delivered through 
gene gun. 
3.5. Virus-Neutralization Activity of Mouse  
Serums 
The neutralizing antibody titers were measured against 
homologous (strain 16681) viruses using pooled sera 
obtained from mice on day 63, 84, and 119 post booster 
immunizations (Table 1). Serum from all immunization 
groups had considerable neutralizing activity kinetically 
against the DENV-2 parental strain 16681 up to four 
months after immunization. Of the routes which deliv-
ered the DNA plasmid, the gg group gave the highest 
neutralization activity with 77% plaque reduction at se-
rum dilution of 400-fold collected on day 63; however, 
the im and gg + im group only gave about 50% of plaque  
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Table 1. Plaque-reduction neutralization activity of serum against DENV-2 from mice immunized by pCBD2. 
Days post immunization 
63 84 119 
Serum dilution 
Mode of immunizationb 
1:100 1:200 1:400 1:100 1:200 1:400 1:100 1:200 1:400 
gg group 97 ± 4a 88 ± 4 77 ± 6 93 ± 3 83 ± 9 78 ± 11 82 ± 12 63 ± 24 35 ± 30 
IM group 93 ± 6 82 ± 11 52 ± 8 76 ± 24 67 ± 27 74 ± 17 87 ± 8 67 ± 14 46 ± 6 
gg + im group 91 ± 3 92 ± 9 50 ± 3 88 ± 11 80 ± 20 80 ± 14 73 ± 22 63 ± 24 52 ± 36 
aData are percentage of virus neutralization from groups of 3 mice immunized against DENV-2 as described in Materials and Methods. Serum samples from 
these mice, collected at the designated days post-immunization were tested by plaque-reduction neutralization test for their ability to neutralize homologous 
strains of DENV-2. bgg group: gene-gun group, IM group: intramuscular group, gg + im group: gene gun followed by intramuscular delivery group as described 
in Materials and Methods. 
 
 
Figure 4. Kinetics of antibody avidity indices (AI) of sera 
from 4-week-old BALB/c mice immunized with plasmid 
DNA by different immunization methods. Solid circle, mice 
immunized by intramuscular (im) inoculation; solid square, 
mice immunized by gene gun (gg); solid triangle, mice im-
munized by gene gun + im. 
 
reduction under the same conditions with statistical sig-
nificance. Interestingly, both im and gg + im groups in-
creased their neutralization activity by yielding 74% and 
80% plaque reduction at serum dilution of 400-fold col-
lected on day 84, which were about the same as given by 
the gg group and then dropped to 46% and 52% on day 
119 post immunization, respectively. The gg group gave 
to only 35% plaque reduction neutralization activity at 
serum dilution of 400-fold collected on day 118, which 
was lower than those yielded by the im or gg + im group. 
The neutralization titers from the sera obtained from 
three groups at day 84 and 119 were not statistically sig-
nificant. These differences in neutralization activity were 
reproducible. The pooled pre-immune serum samples 
from the plasmid DNA immunization group and the se-
rum samples from the control group (mice given vector 
DNA) had little DENV-neutralizing activity (data not 
shown). 
4. Discussion 
The leading candidates for a dengue vaccine are live- 
attenuated viruses (LAV), but it has proven difficult to 
produce LAV vaccines that are satisfactorily attenuated 
and, at the same time, sufficiently immunogenic [13,14]. 
Clearly, there is a reason for exploring alternatives. We 
previously reported that a DENV-2 DNA vaccine, con-
sisting of prM and 80% E (E-1 to E-397) of DENV-2, 
followed by 20% E from JEV membrane-anchoring re-
gion, was able to generate high-titer antibodies in mice 
which persisted for more than 6 months [10]. Dengue 
virus-neutralizing antibodies directed against the virion E 
antigen are thought to play a key role in protection 
against disease, an idea supported directly by passive 
antibody transfer experiments in animal models and in-
directly by epidemiological data from protective studies 
in areas where dengue is endemic [39,40]. However, the 
level and quality of antibody titers have not been estab-
lished for dengue, and these might differ depending on 
the vaccine administration route. In the present study, we 
further evaluated different routes of immunizations in 
mice by measuring the kinetics of the DENV-2 type- 
specific antibody, antibody avidity, T cell-mediated cy-
tokine responses, and neutralizing activity against wild 
type viruses. This is the first report that compares differ-
ent administration routes for delivering a DNA vaccine, 
which adds further support for the utility of dengue DNA 
vaccines. 
DNA vaccines have shown great potential in their 
ability to elicit potent humoral and cytotoxic cellular 
immune responses against the plasmid-encoded protein 
in a broad range of hosts [29,41,42]. In our study, the 
response observed following gene gun vaccination was 
more prominent, appearing earlier and resulting in higher 
and longer antibody titers than those seen with im injec-
tion. This result indicated that the gene gun technique is 
more efficient in eliciting a serum antibody response. 
This corresponds well with previous observations in mice, 
where particle bombardment of the epidermis gave rise 
to an increase in serum immunoglobulin by injecting 
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DNA directly into the epidermal Langerhans cells, while 
im injection, targeting the muscle cells, is more efficient 
at inducing type 1 cellular immunity [26,43]. The effi-
cient antibody response induced by gene gun vaccination, 
and the fact that im injection requires 100 times more 
DNA per vaccination than gene gun vaccinations, make 
the gene gun techniques appear to be a more effective 
way to deliver a DNA vaccine.  
Various routes and doses of DNA vaccines have been 
used in mouse models previously. Intramuscular immu-
nization by DNA plasmid expressing the secretory Japa-
nese encephalitis virus (JEV) envelope protein induced 
higher anti-E antibody responses and end-point antibody 
titers than gene gun immunization [27]. However, in the 
result of the pig model, obtained by using the nucleopro-
tein of the porcine reproductive and respiratory syndrome 
virus as an antigen, suggested that gene gun delivery 
elicits a higher and more efficient immune response than 
im injection [43]. Similar results can also be seen in a 
DNA immunization mouse model when using plasmids 
expressing prM and E of the tick-borne encephalitis virus 
[26]. In our study, both vaccination techniques were effi-
cient in eliciting an immune response, giving rise to spe-
cific serum antibody responses. However, the response 
observed following gene gun vaccination was more 
prominent, appearing earlier and resulting in higher and 
longer antibody titers than those seen with im injection. 
The explanation for the longevity of the antibody re-
sponse after gene gun delivery could be due to the per-
sistence of functional antigen-presenting dendritic cells 
for up to one month [28]. Compared to gene gun delivery, 
the ability to raise antibodies had been lost in im-immu- 
nized mice, in which the antigen-presenting dendritic 
cells were not detectable in lymphoid nodes after being 
immunized for one month [28].  
DNA immunization is thought to elicit immune re-
sponses that closely resemble those seen though natural 
infections with intracellular pathogens. An important 
feature of the DNA vaccine is that antigen synthesis oc-
curs intracellularly, allowing the processed antigen to 
enter the MHC class I pathway [44]. The previous study 
indicated that DNA vaccination favors memory rather 
than effector B cell responses [29]. In our experiments, 
priming with a DNA vaccine by gene gun delivery fol-
lowed by a boosting after a second immunization by im 
delivery did not shift the immune response from a Th2 to 
Th1 response. This suggested that the DNA vaccine was 
effective in priming a specific anti-DENV-2 response, 
and apparently generated a broad range of both T-helper 
and B-cell memories. In both intramuscular and gene gun 
DNA immunization routes, the dominated Th1 or Th2 
type immune responses could be efficiently activated 
after boosting. Boosting by a different administration 
route did not alter the isotypic nature of the response 
because of the T-helper memory.  
Cytokines play a pivotal role in immune responses 
against viruses, not only through direct antiviral activity, 
but also by orchestrating a wide range of immune re-
sponses designed to limit infection. We examined the 
responses to immunizations by using routes delivering 
plasmids expressing the prM/E protein to study the pre-
dominant anti-E antibody isotype and the cytokine secre-
tion profile of spleen cells from immunized mice. Results 
indicated that im inoculation of plasmid DNA encoding 
DENV-2 E protein induced Th1 immune responses, 
whereas the gene-gun-based delivery induced Th2 re-
sponses. The differences in the lymphokine patterns of 
the raised T cells response appeared to be rooted in the 
differences in antigen-presenting cells (APCs) that were 
targeted. After im immunization, gene expression can 
take place in more than one lymphoid tissue and in more 
than one cell type, although only the muscle cell has been 
reported [45]. For gene gun immunization, dendritic cells 
are the major APCs, and approximately 5% of the cells 
are epidermal Langerhans cells [46,47]. After im immu-
nization, large amounts of extracellular vaccine DNA is 
then taken up by resident and migrant cells, which induce 
a Th1 response through activation of the Toll-like recep-
tor 9 (TLR9) [48]. In contrast, gene gun immunization 
delivers DNA coated onto gold beads directly into cells, 
largely bypassing TLR9 and inducing a Th2 response 
[49]. Our findings regarding the type of T helper cell 
immune response generated by im or gene gun-based 
delivery of DNA are consistent with the general pattern 
observed by others using various plasmid DNA con-
structs [26-28,41].  
DENV infection produces a mild acute DF, and a life 
threatening DHF and DSS. The precise mechanism of 
DHF/DSS is not yet fully known. The important hy-
potheses put forward regarding the role of host factors 
are antibody-dependent enhancement (ADE) of DENV 
replication, shift of Th1 to Th2-type cytokine response 
and other T cell responses resulting into cytokine storm 
[4,50]. It is possible that the gene gun-based delivery 
system shown in this study will exacerbate the immune 
response by re-infection after DNA vaccination [51]. 
Since boosting by a different administration route such as 
im did not alter the response from Th2 to Th1 as shown 
in this study, future efforts should focus on other alterna-
tives for DNA delivery to improve the efficiency of DNA 
vaccination, such as liposome encapsidation, electropo-
ration or high pressure gene gun apparatus [52-54].  
We also determined the antibody avidity index, which 
is an approximate measure of the strength or stability of 
an antibody-antigen interaction. High-avidity antibodies 
might be conductive for maintaining dengue viruses in a 
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neutralized state. For most animals, the antibody avidity 
index increased since the last booster immunization, 
from low affinity of two weeks after the booster to 3 
months after vaccination, possibly as a result of affinity 
maturation. The highest average antibody avidity index 
on day 63 was seen in the im vaccine group followed by 
the gg + im and gg group. However, contrasting with the 
higher neutralizing antibody titers observed in the gg 
group on the same day, higher antibody avidity in the im 
vaccine group didn’t correlate with higher neutralizing 
antibody titers. Likewise, Simmons et al reported that the 
DNA vaccination group by gene gun delivery produced a 
significantly high avidity index (>30), which did not 
correlate with the reduction of the duration of viremia 
[25]. In our study, the mice from the gg group produced 
the lowest antibody avidity among the three groups, 
probably due to the antibody subclass IgG1; however, the 
neutralizing activity was more correlated with the total 
antibodies produced by the gene gun method in the gg 
group. Therefore, our results suggested that total anti-
bodies containing both neutralizing and nonneutralizing 
antibodies present at high titers are important for neu-
tralization in vitro in this model. 
In summary, our results suggest that a DNA vaccine 
delivered by the gene gun route produced higher and 
longer total antibody titers as measured by ELISA. The 
high quantity of antibody titers correlates with the ob-
served higher neutralizing activity against homologous 
wild type viruses but not with antibody avidity or anti-
body subclasses. This vaccine may provide an alternative 
for LAV vaccines in dengue virus immunizations, possi-
bly having a lower risk for immediate reactogenicity. 
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